Annals of Pediatric Cardiology

7,700 Resident Physicians Placed into Fellowship Training Positions through the NRMP's Medicine and Pediatric Specialties Match

Retrieved on: 
Wednesday, November 29, 2023
Pediatrics, Cardiovascular disease, Annals of Pediatric Cardiology, Workforce, Cardiology, Medicine, National Resident Matching Program, Rheumatology, Patient, Immunology, BSN, Internal medicine, COVID-19, Hematology, NRMP, Doctor of Health Science, Geriatrics, MD, MBA, Ageing, Interventional pulmonology, Growth, Infection, Critical Care Medicine (journal), Nursing, Dentistry, Match, Gastroenterology, Oncology

WASHINGTON, Nov. 29, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) has released results for the 2023 Medicine and Pediatric Specialties Match, its largest fellowship Match encompassing 38 subspecialties. The 2023 Match featured an all-time high of 3,482 programs that certified a rank order list, marking a 3.6 percent increase in the number of programs over 2022. These programs collectively offered 9,068 positions, a 3.9 percent increase with 344 more positions than the previous year. Of these positions, 7,723 (85.2 percent) were filled when the matching algorithm was processed. While both the number of programs and positions increased by over three percent, the number of applicants certifying a rank order list for the Match saw a modest rise of only 35 applicants or 0.4 percent.

Key Points: 
  • WASHINGTON, Nov. 29, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) has released results for the 2023 Medicine and Pediatric Specialties Match, its largest fellowship Match encompassing 38 subspecialties.
  • "The growth of fellowship programs and positions in the Match reflect training opportunities and the future workforce trends of medical subspecialties.
  • Pediatric specialties offered 1,878 certified positions, filling 1,487 positions (79.2 percent), a decrease of 5.5 percent compared to last year.
  • Pediatric specialties filling over ninety-five percent of their positions include Pediatric Cardiology and Pediatric Hospital Medicine.

Rady Children's Hospital Appoints Adel Younoszai, MD, as Rady Children's Hospital Co-Director of the Heart Institute, and Division Chief of Cardiology, Department of Pediatrics, UC San Diego

Retrieved on: 
Tuesday, October 3, 2023
University of California, San Diego, Ventricular septal defect, University, College of Medicine, Harvard University, Health care, University of Ottawa Heart Institute, Rady Children's Hospital, UCSD, Research, Annals of Pediatric Cardiology, Harvard T.H. Chan School of Public Health, Public health, University of Colorado School of Medicine, UC, MD, Patient, Division, SAN, Child, Neuroscience, Hospital, Pediatric nursing, Dean (education), Nursing, Pediatrics, Cardiology, Echocardiography

Dr. Younoszai will spearhead the evolution of the cardiology department by embracing the technological advancements to empower providers to deliver faster more effective care and improve outcomes.

Key Points: 
  • Dr. Younoszai will spearhead the evolution of the cardiology department by embracing the technological advancements to empower providers to deliver faster more effective care and improve outcomes.
  • "Dr. Younoszai's accomplishments in clinical care, research and in leadership roles are truly impressive."
  • "His accomplishments in clinical care, research and in leadership roles are truly impressive and we're so fortunate to have him join Rady Children's and UC San Diego."
  • "He will be a great Cardiology Chief for our institution, and he joins us at the right time.

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

Retrieved on: 
Thursday, September 21, 2023
Leona, HSCS, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital (Manhattan), Cardiovascular disease, ECG, Intelligence, Research, Doctor of Philosophy, Assistant, Annals of Pediatric Cardiology, Cardiac electrophysiology, Science, Patent, Patient, Division, Mount Sinai Hospital, Algorithm, Machine learning, Cardiology, Diagnosis, Policy, MPH, Mount Sinai Health System, Death, D3M, Medical device, Management, Pharmaceutical industry, MD, Medicine

HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.

Key Points: 
  • HeartSciences has entered into licenses covering rights to a variety of Icahn Mount Sinai’s AI algorithms, technologies and patent filings for the screening and diagnosis of cardiovascular disease.
  • HeartSciences and Icahn Mount Sinai have also entered into a memorandum of understanding for ongoing cooperation encompassing de-identified data access, on-going research, and the evaluation of HeartSciences’ MyoVista® wavECGTM.
  • Mount Sinai and Mount Sinai faculty, including Dr. Nadkarni; Dr. Vaid; Joshua Lampert, MD, Medical Director of Machine Learning for Mount Sinai Heart; Vivek Reddy, MD, Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn Mount Sinai; and Son Duong, MD, Assistant Professor of Pediatrics (Pediatric Cardiology) at Icahn Mount Sinai, have a financial interest in this technology and in HeartSciences.
  • The financial interest of Mount Sinai faculty is pursuant to the Mount Sinai Intellectual Property Policy.

Outcomes Data Reveal Significant Impact of Etiometry Utilization in Liberating Patients from Invasive ICU Treatments

Retrieved on: 
Monday, August 28, 2023
Managed Care, Software, Research, Technology, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Cardiology, Nursing, Practice Management, Health, Hospice and palliative medicine, Risk, University of Alabama, Probability, University, HLA, Lactic acid, Perfusion, MSHA, Quality, Associate, Annals of Pediatric Cardiology, Harvard Medical School, Charles Mullins (pediatric cardiologist), Congress, Hospital, ERT, Metabolic acidosis, Assistant professor, Medical director, Patient, Division, Algorithm, Disease, ICU, Analytics, FDA, Weaning, MPH, Pelvic floor dysfunction, Automation, Medical device, Pharmaceutical industry, Pediatrics, MD

Etiometry’s Risk Analytics provide an individualized assessment of the patient’s condition, bringing attention to patients who need it most and revealing insight into the cause of potential deterioration or improvement to a patient's state.

Key Points: 
  • Etiometry’s Risk Analytics provide an individualized assessment of the patient’s condition, bringing attention to patients who need it most and revealing insight into the cause of potential deterioration or improvement to a patient's state.
  • Extubation failure is associated with significant morbidity, including prolonged total ventilation time and longer hospital length of stay.
  • The findings reveal the new automated standardized workflow in Etiometry informed data-driven decisions leading to an 18% reduction of time with vasoactive infusions.
  • The data are compelling, especially in terms of how our clinical intelligence can enhance patient care,” said Shane Cooke, CEO of Etiometry.

Ochsner Medical Center Ranked #1 in Louisiana for the 12th Consecutive Year by U.S. News & World Report

Retrieved on: 
Tuesday, August 1, 2023
U.S. News & World Report Best Hospitals Rankings, ENT, OMC, Surgeon, Kidney failure, Prostate cancer, Audiology, Nation, Ochsner Health System, Hospital, Lymphoma, Nursing, Ochsner Medical Center – West Bank, Annals of Pediatric Cardiology, Chronic obstructive pulmonary disease, Otorhinolaryngology, Percutaneous aortic valve replacement, Nose, Pulmonology, MD, Patient, Physician, Journal of Neurology, Neurosurgery, and Psychiatry, Cardiology, Diabetes, Heart failure, Ochsner Baptist Medical Center, Digestive system surgery, Ear, News, Pharmaceutical industry, Pneumonia, Stroke, U.S. News & World Report, U.S, Leukemia

NEW ORLEANS, Aug. 1, 2023 /PRNewswire/ -- Ochsner Medical Center - New Orleans (OMC), inclusive of Ochsner Medical Center- West Bank and Ochsner Baptist, has been named by U.S. News & World Report to its 2023-2024 Best Hospitals, marking the 12th consecutive year ranked as the Best Hospital in Louisiana. Additionally, OMC is the #1 hospital in the New Orleans metro area. Ochsner is also home to U.S. News' top-ranked hospital for kids in Louisiana – Ochsner Hospital for Children.

Key Points: 
  • NEW ORLEANS, Aug. 1, 2023 /PRNewswire/ -- Ochsner Medical Center - New Orleans (OMC), inclusive of Ochsner Medical Center- West Bank and Ochsner Baptist , has been named by U.S. News & World Report to its 2023-2024 Best Hospitals , marking the 12th consecutive year ranked as the Best Hospital in Louisiana.
  • Ochsner is also home to U.S. News' top-ranked hospital for kids in Louisiana – Ochsner Hospital for Children .
  • Ochsner Medical Center - New Orleans (OMC) has been named by U.S. News & World Report to its 2023-2024 Best Hospitals.
  • As part of the annual review, Ochsner hospitals also received more than 30 additional accolades from U.S. News, including Ochsner Lafayette General Medical Center (OLGMC), inclusive of Ochsner Lafayette General Surgical Hospital , Ochsner Lafayette General Orthopedic Hospital and Ochsner Cancer Center of Acadiana , ranking as the best hospital in Southwestern Louisiana.

Etiometry Gains FDA Clearance of AI-Based Algorithm that Alerts Risk of Hypercapnia for Neonates in Critical Care

Retrieved on: 
Tuesday, August 1, 2023
Cardiology, Data Management, Technology, FDA, Other Health, Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Hospitals, Abstract, NICU, PCO2, Multimedia, Hypercapnia, Annals of Pediatric Cardiology, Congress, Food and Drug Administration Amendments Act of 2007, Patient, Risk, Picus, Digital, Nursing care plan, ICU, Intensive care unit, Environment, Food, Medical device, Nursing

View the full release here: https://www.businesswire.com/news/home/20230801099358/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230801099358/en/
    Etiometry’s IVCO2 Index™ alerts risk of hypercapnia in critical care patients.
  • This algorithm was recently FDA cleared for use on neonates.
  • Vigilant monitoring for hypercapnia is critical for maximizing neurodevelopmental outcomes and preventing complications in these fragile patients.
  • “The IVCO2 Index™ is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients,” said Dimitar Baronov, CTO of Etiometry.

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

Retrieved on: 
Thursday, July 6, 2023
Triple-negative breast cancer, TNBC, ER, Breast, Cancer, Woman, Research, Atossa, Annals of Pediatric Cardiology, SERM, Seminal vesicles, Patient, Risk, Cardiology, Weill Cornell Medicine, Neoplasm, Progesterone, Therapy, Recurrence, Estrogen receptor, Phenotype, Metastasis, Breast cancer, Medical imaging, Birth control

SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC).

Key Points: 
  • SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC).
  • “We look forward to working with Atossa and think this project could provide proof of principle for novel approaches to estrogen receptor reinduction in triple negative breast cancer,” said Dr. Lyden.
  • “It’s called triple-negative breast cancer because it does not have any of the receptors that are commonly found in most breast cancers.
  • Activating the estrogen receptor and converting the tumor to ER+ would fundamentally transform the treatment paradigm for these patients.”

Hassenfeld Children's Hospital at NYU Langone is No. 1 in New York for Pediatric Cardiology & Heart Surgery

Retrieved on: 
Tuesday, June 27, 2023
Survival rate, Congenital Heart Surgeons' Society, Heart, Society, Partnership, CHSD, Ventricular septal defect, Hospital, NYU, Hope, Birth defect, MBA, Children's Hospital, Annals of Pediatric Cardiology, U.S. News & World Report, Transplant, Cardiothoracic surgery, MD, Patient, Division, Nursing, Risk, Cardiology, Hassenfeld Children's Hospital, NYU Langone Health, Faculty, Gabriel Andral, PAT, Social work, News, Anesthesiology, Dentistry, Pediatrics

NEW YORK, June 27, 2023 /PRNewswire/ -- Hassenfeld Children's Hospital at NYU Langone is the highest ranked in New York for pediatric cardiology and heart surgery care, based on the national specialty ranking in the 2023-2024 U.S. News & World Report's "Best Children's Hospitals" guide released this week.

Key Points: 
  • NEW YORK, June 27, 2023 /PRNewswire/ -- Hassenfeld Children's Hospital at NYU Langone is the highest ranked in New York for pediatric cardiology and heart surgery care, based on the national specialty ranking in the 2023-2024 U.S. News & World Report's "Best Children's Hospitals" guide released this week.
  • "We are immensely proud to be recognized, validating our commitment to deliver high-quality, family-centered care to those who need us most."
  • "These successful outcomes are why Hassenfeld Children's Hospital is a recognized leader in the multidisciplinary care of pediatric heart conditions."
  • Congenital heart surgery at Hassenfeld Children's Hospital is a national leader performing nearly 250 operations annually on the full spectrum of pediatric and adult congenital heart disease including transplantation.

Children's Hospital of Philadelphia Receives Multi-Million Dollar Gift from Topolewski Family to Advance Pediatric Heart Valve Research and Establish Endowed Chair in Cardiology

Retrieved on: 
Thursday, May 18, 2023
Surgeon, Ventricular septal defect, The Center, CHOP, Heart valve repair, Medulla oblongata, FACC, Cardiovascular disease, Research, Cora, Cardiology, Frontier, VSD, Patient, Division, Map, Mortimer, Knowledge, Infant, Hospital, Topolewski v. State, Children's Hospital of Philadelphia, Pharmaceutical industry, Dentistry, Medical device, Nursing, Annals of Pediatric Cardiology, FAAP, MD

PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .

Key Points: 
  • PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .
  • The Topolewski Pediatric Heart Valve Center brings together a comprehensive team of cardiac surgeons, cardiologists, scientists, researchers, and experts in interventional cardiology and cardiac imaging to revolutionize pediatric cardiac care.
  • This multidisciplinary group takes a coordinated approach and is working to develop precise, evidence-based long-term solutions for infants and children with heart valve disease.
  • As part of the Topolewski family gift, Dr. Jolley will hold the inaugural Topolewski Endowed Chair in Pediatric Cardiology.

MiCare Path Joins the Innovators' Network at American Heart Association (AHA) Center for Health Technology & Innovation and Will Integrate AHA Digital Science-Based CarePlans into Its Platform

Retrieved on: 
Wednesday, November 2, 2022
Online, American Heart Association, MPH, 2009 Davis Cup, FRCPE, Organization, NIH, MHealth, Department, FESC, Hospital, Man, FAHA, American College of Cardiology, Center, Solution, Science, Risk, Korea Disease Control and Prevention Agency, CEO, Stanford University, Health, Partnership, Collaborative innovation network, Division, Blood pressure, National Center for Health Statistics, Technology, Degenerative disease, AHA, Health education, Innovation, Patient, Multimedia, CDC, Le Bonheur Children's Hospital, Sleep, Diet, Physician, Centers for Disease Control and Prevention, St. Jude Children's Research Hospital, Volunteering, Woman, FAAP, Annals of Pediatric Cardiology, National, Tablet, Death, Cholesterol, Adult, FACC, GA, Medicine, Blood, Association, Medical statistics, Medical device, Pharmaceutical industry, MD, Cardiology, Network, Facebook

MEMPHIS, Tenn., Nov. 2, 2022 /PRNewswire/ -- MiCare Path, a platform that optimizes patient care through remote patient monitoring, has joined the AHA for Health Technology & Innovation's Innovators' Network (the Center). The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. MiCare Path will utilize CarePlans and digital science to deliver the future of healthcare, today.

Key Points: 
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • MiCare Path will utilize CarePlans and digital science to deliver the future of healthcare, today.
  • Innovators' Network members also have access to the Association's digital guidelines, recommendations and premier science as they develop digital healthcare technologies.
  • The National Institutes of Health (NIH) defines mHealth as: the use of mobile and wireless devices (cell phones, tablets, etc.)